Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

NO /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer.

Wang L, Tang W, Yang S, He P, Wang J, Gaedcke J, Ströbel P, Azizian A, Ried T, Gaida MM, Yfantis HG, Lee DH, Lal A, Van den Eynde BJ, Alexander HR, Ghadimi BM, Hanna N, Hussain SP.

Int J Cancer. 2019 Oct 14. doi: 10.1002/ijc.32733. [Epub ahead of print]

PMID:
31609478
2.

Expression of the scaffold connector enhancer of kinase suppressor of Ras 1 (CNKSR1) is correlated with clinical outcome in pancreatic cancer.

Quadri HS, Aiken TJ, Allgaeuer M, Moravec R, Altekruse S, Hussain SP, Miettinen MM, Hewitt SM, Rudloff U.

BMC Cancer. 2017 Jul 21;17(1):495. doi: 10.1186/s12885-017-3481-4.

3.

Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer.

Wang J, Yang S, He P, Schetter AJ, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Gaida MM, Hanna N, Alexander HR, Hussain SP.

Clin Cancer Res. 2016 Dec 15;22(24):5992-6001. Epub 2016 Jul 8.

4.

Autocrine IL-10 functions as a rheostat for M1 macrophage glycolytic commitment by tuning nitric oxide production.

Baseler WA, Davies LC, Quigley L, Ridnour LA, Weiss JM, Hussain SP, Wink DA, McVicar DW.

Redox Biol. 2016 Dec;10:12-23. doi: 10.1016/j.redox.2016.09.005. Epub 2016 Sep 16.

5.

NO and Pancreatic Cancer: A Complex Interaction with Therapeutic Potential.

Wang J, Hussain SP.

Antioxid Redox Signal. 2017 Jun 10;26(17):1000-1008. doi: 10.1089/ars.2016.6809. Epub 2016 Sep 22. Review.

6.

Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer.

Wang J, He P, Gaida M, Yang S, Schetter AJ, Gaedcke J, Ghadimi BM, Ried T, Yfantis H, Lee D, Weiss JM, Stauffer J, Hanna N, Alexander HR, Hussain SP.

Oncotarget. 2016 Aug 16;7(33):52993-53004. doi: 10.18632/oncotarget.10323.

7.

A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.

Yang S, He P, Wang J, Schetter A, Tang W, Funamizu N, Yanaga K, Uwagawa T, Satoskar AR, Gaedcke J, Bernhardt M, Ghadimi BM, Gaida MM, Bergmann F, Werner J, Ried T, Hanna N, Alexander HR, Hussain SP.

Cancer Res. 2016 Jul 1;76(13):3838-50. doi: 10.1158/0008-5472.CAN-15-2841. Epub 2016 Apr 20.

8.

Pancreatic Cancer: Current Progress and Future Challenges.

Hussain SP.

Int J Biol Sci. 2016 Feb 3;12(3):270-2. doi: 10.7150/ijbs.14950. eCollection 2016.

9.

Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression.

Alam MS, Gaida MM, Bergmann F, Lasitschka F, Giese T, Giese NA, Hackert T, Hinz U, Hussain SP, Kozlov SV, Ashwell JD.

Nat Med. 2015 Nov;21(11):1337-43. doi: 10.1038/nm.3957. Epub 2015 Oct 19.

10.

Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells.

Hara T, Jones MF, Subramanian M, Li XL, Ou O, Zhu Y, Yang Y, Wakefield LM, Hussain SP, Gaedcke J, Ried T, Luo J, Caplen NJ, Lal A.

Oncotarget. 2014 Sep 15;5(17):7635-50.

11.

Metabolic profiles are principally different between cancers of the liver, pancreas and breast.

Budhu A, Terunuma A, Zhang G, Hussain SP, Ambs S, Wang XW.

Int J Biol Sci. 2014 Aug 30;10(9):966-72. doi: 10.7150/ijbs.9810. eCollection 2014.

12.

Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression.

Heinecke JL, Ridnour LA, Cheng RY, Switzer CH, Lizardo MM, Khanna C, Glynn SA, Hussain SP, Young HA, Ambs S, Wink DA.

Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6323-8. doi: 10.1073/pnas.1401799111. Epub 2014 Apr 14.

13.

Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer.

Zhang G, He P, Tan H, Budhu A, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Maitra A, Hanna N, Alexander HR, Hussain SP.

Clin Cancer Res. 2013 Sep 15;19(18):4983-93. doi: 10.1158/1078-0432.CCR-13-0209. Epub 2013 Aug 5.

14.

FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer.

Zhang G, He P, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Hanna N, Alexander HR, Hussain SP.

Cancer Res. 2013 Sep 1;73(17):5416-25. doi: 10.1158/0008-5472.CAN-13-0362. Epub 2013 Jun 25.

15.

Macrophages, nitric oxide and microRNAs are associated with DNA damage response pathway and senescence in inflammatory bowel disease.

Sohn JJ, Schetter AJ, Yfantis HG, Ridnour LA, Horikawa I, Khan MA, Robles AI, Hussain SP, Goto A, Bowman ED, Hofseth LJ, Bartkova J, Bartek J, Wogan GN, Wink DA, Harris CC.

PLoS One. 2012;7(9):e44156. doi: 10.1371/journal.pone.0044156. Epub 2012 Sep 6.

16.

Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.

Funamizu N, Hu C, Lacy C, Schetter A, Zhang G, He P, Gaedcke J, Ghadimi MB, Ried T, Yfantis HG, Lee DH, Subleski J, Chan T, Weiss JM, Back TC, Yanaga K, Hanna N, Alexander HR, Maitra A, Hussain SP.

Int J Cancer. 2013 Feb 15;132(4):785-94. doi: 10.1002/ijc.27736.

17.

NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.

Okayama H, Saito M, Oue N, Weiss JM, Stauffer J, Takenoshita S, Wiltrout RH, Hussain SP, Harris CC.

Int J Cancer. 2013 Jan 1;132(1):9-18. doi: 10.1002/ijc.27644. Epub 2012 Jun 13.

18.

DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.

Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM, Ried T, Hassan R, Yfantis HG, Lee DH, Lacy C, Maitra A, Hanna N, Alexander HR, Hussain SP.

PLoS One. 2012;7(2):e31507. doi: 10.1371/journal.pone.0031507. Epub 2012 Feb 20.

19.

Inflammation regulates microRNA expression in cooperation with p53 and nitric oxide.

Mathé E, Nguyen GH, Funamizu N, He P, Moake M, Croce CM, Hussain SP.

Int J Cancer. 2012 Aug 1;131(3):760-5. doi: 10.1002/ijc.26403. Epub 2011 Nov 1.

20.

Targeted disruption of Ing2 results in defective spermatogenesis and development of soft-tissue sarcomas.

Saito M, Kumamoto K, Robles AI, Horikawa I, Furusato B, Okamura S, Goto A, Yamashita T, Nagashima M, Lee TL, Baxendale VJ, Rennert OM, Takenoshita S, Yokota J, Sesterhenn IA, Trivers GE, Hussain SP, Harris CC.

PLoS One. 2010 Nov 19;5(11):e15541. doi: 10.1371/journal.pone.0015541.

21.

Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy.

Weiss JM, Ridnour LA, Back T, Hussain SP, He P, Maciag AE, Keefer LK, Murphy WJ, Harris CC, Wink DA, Wiltrout RH.

J Exp Med. 2010 Oct 25;207(11):2455-67. doi: 10.1084/jem.20100670. Epub 2010 Oct 4.

22.

Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line.

Jiang W, Wang XW, Unger T, Forgues M, Kim JW, Hussain SP, Bowman E, Spillare EA, Lipsky MM, Meck JM, Cavalli LR, Haddad BR, Harris CC.

Int J Cancer. 2010 Sep 1;127(5):1011-20. doi: 10.1002/ijc.25118.

23.

Nitric oxide is a key component in inflammation-accelerated tumorigenesis.

Hussain SP, He P, Subleski J, Hofseth LJ, Trivers GE, Mechanic L, Hofseth AB, Bernard M, Schwank J, Nguyen G, Mathe E, Djurickovic D, Haines D, Weiss J, Back T, Gruys E, Laubach VE, Wiltrout RH, Harris CC.

Cancer Res. 2008 Sep 1;68(17):7130-6. doi: 10.1158/0008-5472.CAN-08-0410.

24.

Inflammation and cancer: is AID aiding?

Hussain SP.

Gastroenterology. 2008 Sep;135(3):736-7. doi: 10.1053/j.gastro.2008.07.035. Epub 2008 Aug 8. No abstract available.

25.

The reemergence of nitric oxide and cancer.

Wink DA, Ridnour LA, Hussain SP, Harris CC.

Nitric Oxide. 2008 Sep;19(2):65-7. doi: 10.1016/j.niox.2008.05.003. Review. No abstract available.

26.

Inflammation and cancer: an ancient link with novel potentials.

Hussain SP, Harris CC.

Int J Cancer. 2007 Dec 1;121(11):2373-80. Review.

27.

TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.

Hussain SP, Schwank J, Staib F, Wang XW, Harris CC.

Oncogene. 2007 Apr 2;26(15):2166-76. Review.

PMID:
17401425
28.

Quantitative detection of p53 mutations in plasma DNA from tobacco smokers.

Hagiwara N, Mechanic LE, Trivers GE, Cawley HL, Taga M, Bowman ED, Kumamoto K, He P, Bernard M, Doja S, Miyashita M, Tajiri T, Sasajima K, Nomura T, Makino H, Takahashi K, Hussain SP, Harris CC.

Cancer Res. 2006 Aug 15;66(16):8309-17.

29.

Regulation of human nitric oxide synthase 2 expression by Wnt beta-catenin signaling.

Du Q, Park KS, Guo Z, He P, Nagashima M, Shao L, Sahai R, Geller DA, Hussain SP.

Cancer Res. 2006 Jul 15;66(14):7024-31.

30.

Superoxide fluxes limit nitric oxide-induced signaling.

Thomas DD, Ridnour LA, Espey MG, Donzelli S, Ambs S, Hussain SP, Harris CC, DeGraff W, Roberts DD, Mitchell JB, Wink DA.

J Biol Chem. 2006 Sep 8;281(36):25984-93. Epub 2006 Jul 7.

31.
32.

The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress.

Staib F, Robles AI, Varticovski L, Wang XW, Zeeberg BR, Sirotin M, Zhurkin VB, Hofseth LJ, Hussain SP, Weinstein JN, Galle PR, Harris CC.

Cancer Res. 2005 Nov 15;65(22):10255-64.

33.

Chronic inflammation promotes retinoblastoma protein hyperphosphorylation and E2F1 activation.

Ying L, Marino J, Hussain SP, Khan MA, You S, Hofseth AB, Trivers GE, Dixon DA, Harris CC, Hofseth LJ.

Cancer Res. 2005 Oct 15;65(20):9132-6.

34.

Nitric oxide, a mediator of inflammation, suppresses tumorigenesis.

Hussain SP, Trivers GE, Hofseth LJ, He P, Shaikh I, Mechanic LE, Doja S, Jiang W, Subleski J, Shorts L, Haines D, Laubach VE, Wiltrout RH, Djurickovic D, Harris CC.

Cancer Res. 2004 Oct 1;64(19):6849-53.

35.

Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease.

Goodman JE, Hofseth LJ, Hussain SP, Harris CC.

Environ Mol Mutagen. 2004;44(1):3-9. Review.

PMID:
15199542
36.

p53: at the crossroads of molecular carcinogenesis and molecular epidemiology.

Hofseth LJ, Robles AI, Yang Q, Wang XW, Hussain SP, Harris C.

Chest. 2004 May;125(5 Suppl):83S-5S. No abstract available.

PMID:
15136428
37.

p53: 25 years after its discovery.

Hofseth LJ, Hussain SP, Harris CC.

Trends Pharmacol Sci. 2004 Apr;25(4):177-81. Review.

PMID:
15116721
38.

p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis.

Hussain SP, Amstad P, He P, Robles A, Lupold S, Kaneko I, Ichimiya M, Sengupta S, Mechanic L, Okamura S, Hofseth LJ, Moake M, Nagashima M, Forrester KS, Harris CC.

Cancer Res. 2004 Apr 1;64(7):2350-6.

39.

TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer.

Olivier M, Hussain SP, Caron de Fromentel C, Hainaut P, Harris CC.

IARC Sci Publ. 2004;(157):247-70. Review.

PMID:
15055300
40.

The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation.

Hofseth LJ, Khan MA, Ambrose M, Nikolayeva O, Xu-Welliver M, Kartalou M, Hussain SP, Roth RB, Zhou X, Mechanic LE, Zurer I, Rotter V, Samson LD, Harris CC.

J Clin Invest. 2003 Dec;112(12):1887-94. Erratum in: J Clin Invest. 2004 Feb;113(3):490.

41.

The role of p53 in base excision repair following genotoxic stress.

Zurer I, Hofseth LJ, Cohen Y, Xu-Welliver M, Hussain SP, Harris CC, Rotter V.

Carcinogenesis. 2004 Jan;25(1):11-9. Epub 2003 Oct 10.

PMID:
14555612
42.

Nitric oxide in cancer and chemoprevention.

Hofseth LJ, Hussain SP, Wogan GN, Harris CC.

Free Radic Biol Med. 2003 Apr 15;34(8):955-68. Review.

PMID:
12684081
43.

Radical causes of cancer.

Hussain SP, Hofseth LJ, Harris CC.

Nat Rev Cancer. 2003 Apr;3(4):276-85. Review.

PMID:
12671666
44.

TP53 and liver carcinogenesis.

Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC.

Hum Mutat. 2003 Mar;21(3):201-16. Review.

PMID:
12619106
45.

Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways.

Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M, Miura K, Harris CC.

Cancer Res. 2003 Feb 1;63(3):728-34.

46.

Nitric oxide-induced cellular stress and p53 activation in chronic inflammation.

Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, Jhappan C, Higashimoto Y, He P, Linke SP, Quezado MM, Zurer I, Rotter V, Wink DA, Appella E, Harris CC.

Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):143-8. Epub 2002 Dec 23.

47.

Molecular pathogenesis of human hepatocellular carcinoma.

Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, Brechot C, Harris CC.

Toxicology. 2002 Dec 27;181-182:43-7. Review.

PMID:
12505283
48.

Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment.

Hussain SP, Hofseth LJ, Harris CC.

Lung Cancer. 2001 Dec;34 Suppl 2:S7-15. Review.

PMID:
11720736
49.

Oxidative stress and p53 mutations in the carcinogenesis of iron overload-associated hepatocellular carcinoma.

Marrogi AJ, Khan MA, van Gijssel HE, Welsh JA, Rahim H, Demetris AJ, Kowdley KV, Hussain SP, Nair J, Bartsch H, Okby N, Poirier MC, Ishak KG, Harris CC.

J Natl Cancer Inst. 2001 Nov 7;93(21):1652-5. No abstract available.

PMID:
11698570
50.

Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung.

Hussain SP, Amstad P, Raja K, Sawyer M, Hofseth L, Shields PG, Hewer A, Phillips DH, Ryberg D, Haugen A, Harris CC.

Cancer Res. 2001 Sep 1;61(17):6350-5.

Supplemental Content

Loading ...
Support Center